Inozyme Pharma, Inc. (INZY)

Inozyme Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	19.52	20.8	20.83	18.93	10.55	4.59
Research & Development	62.1	54.85	47.85	37.72	46.49	16.22
Operating Expenses	81.62	75.65	68.68	56.65	57.04	20.81
Operating Income	-81.62	-75.65	-68.68	-56.65	-57.04	-20.81
Interest Expense / Income	4.66	3.33	0.26	0	0	0
Other Expense / Income	-9.17	-7.81	-1.88	-0.02	-0.62	-1.08
Pretax Income	-77.11	-71.17	-67.06	-56.62	-56.42	-19.72
Net Income	-77.11	-71.17	-67.06	-56.62	-56.42	-19.72
Shares Outstanding (Basic)	62	52	38	24	11	1
Shares Outstanding (Diluted)	62	52	38	24	11	1
Shares Change	41.29%	37.27%	60.30%	113.46%	832.81%	12.60%
EPS (Basic)	-1.37	-1.37	-1.78	-2.40	-5.11	-16.67
EPS (Diluted)	-1.37	-1.37	-1.78	-2.40	-5.11	-16.67
Free Cash Flow	-77.59	-70.97	-58.17	-48.55	-36.54	-18.95
Free Cash Flow Per Share	-1.26	-1.37	-1.54	-2.06	-3.31	-16.02
EBITDA	-71.14	-66.51	-65.62	-55.57	-56.21	-19.64
Depreciation & Amortization	1.32	1.33	1.18	1.05	0.22	0.08
EBIT	-72.45	-67.84	-66.8	-56.62	-56.42	-19.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).